BASi Launches Culex NxT Next Generation In Vivo Automated Sampling System
WEST LAFAYETTE, Ind. -- December 27, 2012
BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI) today announced the launch of
Culex^® NxT, the latest generation of the Company’s proprietary in vivo
automated sampling system. The Company is now taking orders for Culex NxT and
expects to begin shipping in January.
Developed by BASi to collect pharmacokinetic and pharmacodynamic data, the
Culex system can automatically collect blood, bile, metabolites, dialysates
and more from awake and freely moving animals as small as mice and as large as
swine. The system is used by nine of the world’s top ten pharmaceutical
companies, universities, and contract research organizations.
"Scientists choose Culex over manual sampling because it delivers better data,
which leads to better decision-making," said Candace Rohde-Johnson, director
of BASi's Instruments Division. "Incorporating innovative hardware and
software improvements, the new Culex NxT has the same small footprint, robust
design and ease of use of the original, providing its users peace of mind when
away from the lab. Culex’s ability to run experiments around the clock versus
just during business hours significantly increases our clients' efficiency and
productivity in the early stages of drug discovery, including safety
Rohde-Johnson continued, "Culex NxT incorporates what we have learned from
Culex enthusiasts in industry and academia who share best practices, attend
annual user meetings and provide their insights online. The improved tubing
sets, optics, wireless notifications, quieter operation and in-line glucose
monitoring are just some of the improvements built on this foundation,
solidifying Culex as the preferred instrumentation for automated sampling.
We've also made it easy for current owners to seamlessly and cost-effectively
upgrade their existing systems."
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related
to changes in the market and demand for our products and services, the
development, marketing and sales of products and services, changes in
technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
Bioanalytical Systems, Inc.
Interim President & CEO and CFO
Neil Berkman, 310.477.3118
Press spacebar to pause and continue. Press esc to stop.